Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085839 · ClinicalTrials.gov registry record · Phase 2
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
A Phase 2 study, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT00085839 is a Phase 2 study that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 103 participants.
The verdict
NCT00085839, a Phase 2 study, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.
Interventions
- DRUG Tarceva (Trademark) (erlotinib HCl, OSI-774)
- DRUG Combination carboplatin and paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085839
The ClinicalTrials.gov registry entry for NCT00085839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tarceva (Trademark) (erlotinib HCl, OSI-774) is the first listed.
NCT00085839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085839 about?
NCT00085839 is a clinical study titled "Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2". The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The stud...
What is the current status of trial NCT00085839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2004-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00085839?
The interventions under investigation include: Tarceva (Trademark) (erlotinib HCl, OSI-774) (DRUG), Combination carboplatin and paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00085839?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.